SCHEMBL29939653

SCHEMBL29939653

CCOC(=O)c1c(-c2ccc(N)cc2F)nn2cccnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
PRKCZ Q05513 1/20 0.39
JAK2 O60674 2/20 0.39
JAK3 P52333 2/20 0.39
PDE4D Q08499 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
TGFBR1 P36897 1/20 0.38
PDE2A O00408 1/20 0.38
ALOX5 P09917 1/20 0.37
TSHR P16473 2/20 0.37
POLB P06746 1/20 0.37
SLC34A1 Q06495 1/20 0.37
PIK3CD O00329 1/20 0.37
PIK3R1 P27986 1/20 0.37
PIK3CG P48736 1/20 0.37
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29939370 0.90 SLC34A1 (0.45) MAPTKDM4EALDH1A1JAK2JAK3
SCHEMBL27230012 0.89 ALOX5 (0.41) MAPTKDM4EALDH1A1SMN1; SMN2TGFBR1
SCHEMBL27230050 0.88 KDM4E (0.38) KDM4EALDH1A1JAK2JAK3TGFBR1
SCHEMBL30029164 0.87 PRKCZ (0.49) MAPTKDM4EALDH1A1PRKCZJAK2
SCHEMBL27230024 0.87 CHRNA7 (0.40)
SCHEMBL29939563 0.86 JAK2 (0.47) MAPTKDM4EALDH1A1JAK2JAK3
SCHEMBL27230037 0.86 KCNQ3 (0.38) KDM4EALDH1A1SMN1; SMN2TGFBR1PDE2A
SCHEMBL30988108 0.85 KCNQ3 (0.39) KDM4EALDH1A1JAK2JAK3SMN1; SMN2
SCHEMBL30988102 0.85 PTGS2 (0.46) TGFBR1PDE2ASLC34A1PIK3CDPIK3CG
SCHEMBL29939613 0.85 PDE2A (0.42) MAPTKDM4EALDH1A1PRKCZJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12227507-B2 Pharmaceutical compounds PFIZER INC. (US) 2025-02-18 US disclosed
US-11634425-B2 Pharmaceutical compounds PFIZER INC. (US) 2023-04-25 US disclosed
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-10-13 US disclosed
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12227507-B2 Pharmaceutical compounds CHRNA6, GABRA6, CHRNA7 MAPT 2049/4885KDM4E 4162/4885ALDH1A1 3480/4885
US-11634425-B2 Pharmaceutical compounds GABRA6, CHRNA6, CNR1 MAPT 2305/4885KDM4E 3774/4885ALDH1A1 3010/4885
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS CHRNA6, GABRA6, CHRNA7 MAPT 2049/4885KDM4E 4162/4885ALDH1A1 3480/4885
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS GABRA6, CNR1, CHRNA6 MAPT 2068/4885KDM4E 3752/4885ALDH1A1 3112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.